1. Home
  2. BTBD vs ALZN Comparison

BTBD vs ALZN Comparison

Compare BTBD & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

HOLD

Current Price

$1.75

Market Cap

7.1M

ML Signal

HOLD

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.71

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBD
ALZN
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
7.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BTBD
ALZN
Price
$1.75
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
36.9K
83.8K
Earning Date
05-15-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.77
EPS
N/A
N/A
Revenue
$14,823,472.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.84
52 Week High
$2.48
$2.68

Technical Indicators

Market Signals
Indicator
BTBD
ALZN
Relative Strength Index (RSI) 76.25 65.28
Support Level $1.53 $1.41
Resistance Level $1.67 $2.25
Average True Range (ATR) 0.08 0.11
MACD 0.02 0.00
Stochastic Oscillator 90.91 90.32

Price Performance

Historical Comparison
BTBD
ALZN

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Share on Social Networks: